Vascular Closure Device Market - By Device Type, By Access, By End Use - Global Forecast, 2025-2034

Vascular Closure Device Market Size

The global vascular closure device market was valued at USD 1.74 billion in 2024. The market is expected to grow from USD 1.82 billion in 2025 to USD 3 billion in 2034, growing at a CAGR of 5.7% during the forecast period, according to the latest report published by Global Market Insights Inc. The high market growth is attributed to the rising prevalence of cardiovascular diseases, growth in interventional cardiology and radiology procedures, benefits of vascular closure devices over traditional methods, and growing shift toward outpatient and same-day discharge procedures, among other contributing factors.

Vascular closure device is a medical device used to achieve hemostasis after catheterization procedures by sealing the hole in the femoral or radial artery. It is more efficient than or can be combined with manual compression, thus cutting the time for bleeding cessation and patient rest. These devices may use mechanical clips, sutures, or collagen plugs to close the arterial puncture effectively.
 

The leading players in the vascular closure device market include Abbott, Cordis, HAEMONETICS, Medtronic, and TERUMO. These organizations keep up their advantage over rivals through continuous device-type innovation, a worldwide presence of the market, and considerable expenditures on research and development.
 

The market has increased from USD 1.34 billion in 2021 and reached USD 1.65 billion in 2023, with the historic growth rate of 8.6%. The market growth was driven by the rising number of cardiovascular interventions, increasing adoption of minimally invasive procedures, and growing demand for faster patient recovery with reduced hospital stay.
 

Moreover, the rising prevalence of cardiovascular diseases, including coronary artery disease, peripheral vascular disease, and heart failure, has increased the number of angiography and interventional procedures worldwide. For instance, according to the World Health Organization (WHO), cardiovascular diseases caused 20.5 million deaths globally in 2021, representing 32% of all deaths. The American Heart Association reported that in 2023, approximately 92.1 million adults in the U.S. were living with some form of cardiovascular disease, with over 1.5 million cardiac catheterizations performed annually.
 

The Centers for Disease Control and Prevention (CDC) estimates that by 2024, the number of Americans requiring interventional cardiac procedures will increase by 23% compared to 2021 levels. This growth has led to higher demand for vascular closure devices, which are essential for safe and efficient post-procedure care.
 

Furthermore, continuous advancements, such as bioabsorbable closure devices, extravascular sealing systems, and user-friendly designs, are expanding adoption. Newer devices focus on minimizing complications like infection and bleeding, which strengthens market penetration.
 

Vascular Closure Device Market Trends

The market is growing considerably with the shift toward minimally invasive closure techniques, rising adoption of bioabsorbable vascular closure devices, integration of advanced materials and technologies, and expansion in emerging markets, among other factors collectively driving industry growth.
 

• Healthcare providers are increasingly preferring minimally invasive vascular closure methods over manual compression due to faster recovery, fewer complications, and improved patient comfort. This trend is accelerating the adoption of advanced VCDs in hospitals and ambulatory surgical centers.
   
• Further, the adoption of bioabsorbable and extravascular closure systems is also increasing, as these are the most viable options to completely get rid of device removal requirements and minimize long-term complications. Analysis of the FDA data on approval of bioabsorbable closure devices showed that the rate of approval increased by 28% between 2021 and 2023.
   
• The European Medicines Agency reported that the number of incidents threatening patient safety, which are related to traditional closure devices, decreased by 45% in hospitals that made the change to bioabsorbable systems during the period of 2022-2023. A 2023 Medicare database analysis showed that healthcare facilities using these advanced closure systems reported 32% fewer post-procedure complications compared to conventional devices.
   
• Additionally, manufacturers are focusing on developing devices with improved biocompatibility, smaller footprints, and enhanced sealing efficiency. The use of advanced polymers and suture-mediated systems highlights the push toward innovation for higher procedural success rates, thereby sustaining market growth.
   

Vascular Closure Device Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on the device type, the vascular closure device market is segmented into active vascular closure devices and passive vascular closure devices. The active vascular closure devices segment has asserted its dominance in the market by securing a significant market share of 59.3% in 2024 owing to their higher efficacy, faster hemostasis, reduced complication rates, and growing physician preference for suture- and clip-based technologies over manual compression. The segment is expected to exceed USD 1.83 billion by 2034, growing at a CAGR of 6% during the forecast period.
 

On the other hand, the passive vascular closure devices segment is expected to grow with a CAGR of 5.2%. The growth of this segment is driven by their cost-effectiveness, ease of use, lower procedural complexity, and increasing adoption in resource-limited and outpatient settings.
 

• The active vascular closure devices segment continues to dominate the market. Active VCDs, such as suture-mediated or collagen-based devices, allow the fast closure of vascular access sites. As a result, the time of hemostasis is reduced drastically in comparison with manual compression, thus allowing for shorter operations and better cath lab efficiency.
   
• Active devices allow patients to mobilize sooner after procedures, which enhances comfort and reduces bed occupancy. Hospitals benefit from lower costs and improved patient throughput, making these devices highly attractive in interventional settings.
   
• Moreover, the trend of complex interventions such as angioplasty and stent placements has led to active VCDs becoming the preferred choice, as they allow for more dependable closure and fewer complications. The cardiologists' preference is driven by their success in high-risk or large-bore access cases.
   
• The passive vascular closure devices segment held a revenue of USD 706.7 million in 2024, with projections indicating a steady expansion at 5.2% CAGR from 2025 to 2034. The growth of passive vascular closure devices is primarily driven by their cost-effectiveness and simplicity, making them an attractive option for smaller clinics and outpatient centers.
   
• Their non-mechanical design reduces procedural complexity and training requirements, allowing wider adoption among healthcare providers. Additionally, increasing awareness and demand for safe, minimally invasive hemostasis solutions in routine catheterization procedures are supporting market expansion.
   

Based on access, the vascular closure device market is segmented into femoral and radial. The femoral segment dominated the market in 2024, accounting for USD 1.47 billion and is anticipated to grow at a CAGR of 5.9% during the forecast period.
 

• The femoral artery continues to be the primary access site for angiography, angioplasty, and peripheral interventions. The American College of Cardiology stated that in 2023 about 85% of cardiac catheterizations in the U.S. were done via femoral access. In 2022, the Centers for Disease Control and Prevention (CDC) reported that more than 1.2 million femoral artery procedures were performed in the U.S.
   
• Furthermore, the European Society of Cardiology figures revealed that by 2021, the number of interventions carried out by femoral access had come to represent almost 78% of the total across Europe. This predominant use generates a sustained demand for femoral-specific vascular closure devices.
   
• The new suture-mediated, collagen-based and bioabsorbable femoral closure systems have been successful in addressing the needs for enhanced efficacy and lower complication rates. Such improvements encourage more usage by the interventional cardiologists.
   
• The radial segment accounted for significant revenue in 2024 and is anticipated to grow at a CAGR of 4.4% over the forecast period. The increase of this segment is mainly due to the fact that it presents a lower risk of bleeding complications and faster patient recovery when compared to femoral access, hence the trend of radial being the first choice in interventional cardiology is growing. The demand for the specialized closure devices in this segment is driven by the increasing number of radial artery procedures performed in hospitals and cardiac centers.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the vascular closure device market is classified into hospitals, ambulatory surgical centers, and other end users. The hospitals segment dominated the market with a revenue share of 60% in 2024 and is expected to reach USD 1.83 billion within the forecast period.
 

• Hospitals, particularly tertiary care and cardiac centers, are the places where angiography, angioplasty, and catheterization are done in huge numbers. This high procedural volume is the main reason for the constant demand for vascular closure devices that are not only safe for patients but also ensure that the hospital is working efficiently.
   
• Hospitals are mainly concerned with the reduction of complications after the procedure, for example, bleeding, hematoma, or injury to the vessel. VCDs make it possible to get the affected site to bleed in a shorter time which is a lower risk of complications, thus, a hospital’s patient safety and quality care objectives are achieved.
   
• Moreover, hospitals have trained interventional cardiologists and cath lab staff capable of deploying VCDs safely and effectively. This expertise supports confidence in device usage and encourages hospitals to incorporate VCDs into routine practice.
   
• The ambulatory surgical centers segment held a revenue of USD 400.6 million in 2024, with projections indicating a steady expansion at 5.5% CAGR from 2025 to 2034. The segmental growth is driven by their focus on minimally invasive procedures and rapid patient turnover, which require efficient and reliable hemostasis solutions.
   
• The adoption of closure devices in ASCs reduces post-procedural complications and shortens recovery time, enhancing patient satisfaction and throughput. Increasing investment in outpatient cardiac and radiology services further boosts the demand for advanced closure technologies. Additionally, ASCs benefit from cost-effective device usage, supporting broader adoption across smaller healthcare facilities.
   

Looking for region specific data?

Download Free PDF

North America Vascular Closure Device Market
 

North America dominated the market with the highest market share of 44.9% in 2024.
 

• The U.S. vascular closure device market was valued at USD 572.3 million and USD 661.3 million in 2021 and 2022, respectively. The market size reached USD 735.4 million in 2024, growing from USD 700.2 million in 2023, and is anticipated to grow at a CAGR of 5.4% between 2025 to 2034.
   
• North America experiences a high prevalence of cardiovascular diseases, including coronary artery disease, peripheral artery disease, and heart failure. According to the American Heart Association's 2024 statistics, approximately 48% of adults in the U.S. (126.9 million) have some form of cardiovascular disease.
   
• In 2022, the Centers for Disease Control and Prevention (CDC) reported that cardiovascular diseases caused 695,000 deaths in the U.S. The growing number of interventional procedures, including cardiac catheterizations where the figure has exceeded 1.1 million in 2023, creates the demand for vascular closure devices at a high level, as these are the most indispensable devices for vascular closure to be done safely and rapidly.
   
• Additionally, the region has a highly developed healthcare system with modern catheterization labs and extremely qualified interventional cardiologists. This setup is what makes advanced VCDs, such as those that are suture-mediated and collagen-based, be easily accepted, hence gaining pre- and post-procedural efficiency.
   
• Further, there is a strong shift toward minimally invasive cardiovascular interventions in North America to reduce patient recovery time and healthcare costs. VCDs are critical in supporting these procedures by reducing bleeding risk and allowing early ambulation, making them an essential tool in modern cath labs.
   

Europe Vascular Closure Device Market
 

Europe market accounted for USD 520.2 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe faces a growing burden of cardiovascular conditions such as coronary artery disease, peripheral arterial disease, and stroke, particularly in ageing populations. This increase has resulted in a higher number of interventional procedures, therefore, the use of vascular closure devices has gone up to meet the need of those devices which provide rapid hemostasis and lower the risk of complications.
   
• Many European healthcare systems support minimally invasive and outpatient procedures, which they believe will cut down hospitalization costs and improve patient outcomes. Such policies are stimulating hospitals to use VCDs, as they allow the patient to be mobile earlier and the length of stay to be shorter.
   
• Moreover, countries like Germany, France, and the UK have well-equipped catheterization labs and trained interventional cardiologists. This infrastructure enables the safe deployment of both active and passive VCDs, promoting their integration into routine cardiovascular procedures.
   

Asia Pacific Vascular Closure Device Market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 6.8% during the analysis timeframe.
 

• Countries such as China, India, and Japan are heavily investing in modern hospitals, catheterization labs, and specialized cardiovascular centers. The growth of such facilities leads to VCDs usage because hospitals want to have procedural efficiency and the positive patient outcomes.
   
• Healthcare providers along with patients from the area are opting for minimally invasive procedures as opposed to the traditional surgical methods. VCDs are utilized in these operations as they enable the reduction of post-operative bleeding, early ambulation, and increased recovery rate.
   
• Furthermore, governments in countries like India, China, and Singapore are promoting access to advanced cardiovascular care through policies and partnerships with private healthcare providers. Such initiatives improve the availability and adoption of VCDs across both urban and semi-urban centers.
   

Latin America Vascular Closure Device Market
 

The Latin America market is experiencing robust growth over the analysis timeframe.
 

• In Latin America, the vascular closure device (VCD) market is mainly driven by the rising prevalence of vascular diseases such as coronary artery disease and peripheral artery disease, which leads to a higher demand for interventional procedures. Increasing investments in healthcare infrastructure, especially in countries like Brazil and Mexico, are changing the accessibility of modern catheterization labs that have been equipped for advanced VCD usage.
   
• There is an increasing adoption of minimally invasive procedures to reduce recovery time and procedural complications, which further supports device uptake. Government initiatives and public-private partnerships aimed at improving cardiovascular care are enhancing availability and affordability of these devices.
   
• Additionally, hospitals are focusing on operational efficiency, leveraging VCDs to enable early patient ambulation and shorter hospital stays. Awareness among clinicians regarding the safety and efficacy of VCDs compared to manual compression is also encouraging broader adoption across the region.
   

Middle East and Africa Vascular Closure Device Market
 

The Middle East and Africa market is experiencing robust growth over the analysis timeframe.
 

• The regional growth is driven by the increasing prevalence of cardiovascular diseases, fueled by lifestyle changes, obesity, and ageing populations, which leads to higher demand for interventional procedures. Investments in healthcare infrastructure, including advanced catheterization labs in countries like the UAE, Saudi Arabia, and South Africa are improving access to VCDs.
   
• The rising adoption of minimally invasive procedures supports the use of these devices by reducing post-procedural complications and enabling faster patient recovery. Government initiatives and favourable healthcare policies, along with public-private partnerships, are enhancing the availability and affordability of VCDs.
   
• Hospitals and speciality cardiac centers are emphasizing operational efficiency and early patient ambulation, which VCDs facilitate. Additionally, growing clinician awareness of the safety, reliability, and efficacy of VCDs compared to manual compression is promoting broader adoption across the MEA region.
   

Vascular Closure Device Market Share

The market is highly competitive and characterized by the presence of several global and regional players focusing on innovation, product differentiation, and strategic partnerships to strengthen their market positions.
 

Companies are investing in research and development to launch advanced products, such as bioabsorbable, suture-mediated, and extravascular closure devices, aimed at improving procedural efficiency and patient outcomes. Key players include Abbott, Cordis, HAEMONETICS, Medtronic, and TERUMO, collectively accounting for 78.9% of the total market share.
 

Competition is further intensified by mergers, acquisitions, and collaborations aimed at expanding geographic reach and product portfolios. Market players are also adopting strategies such as physician training programs, awareness campaigns, and clinical trials to enhance adoption and demonstrate device efficacy.
 

In addition, pricing strategies, after-sales support, and regulatory approvals play critical roles in differentiating companies in this fast-growing market. Emerging markets in Asia-Pacific, Latin America, and the Middle East and Africa offer growth opportunities, prompting global players to establish distribution networks and partnerships to capture new demand segments.
 

Vascular Closure Device Market Companies

Few of the prominent players operating in the vascular closure device industry include:

• Abbott
• Cordis
• Ensite Vascular
• HAEMONETICS
• Medtronic
• Meril
• MERIT MEDICAL
• Rex Medical
• Teleflex
• TERUMO
• Transluminal Technologies
• Tricol Biomedical
• TZ Medical
• Vasorum
• Vivasure Medical
   
• Abbott

Abbott’s leading the vascular closure device market with a ~36.8% share in 2024, its clinically proven devices like Perclose ProGlide and StarClose SE, offering reliable hemostasis with reduced complication rates. Its strong global presence and integration with interventional cardiology solutions enhance physician trust and widespread adoption.
 

• TERUMO

TERUMO is centred on the Angio-Seal device, known for ease of use, rapid hemostasis, and compatibility with a broad range of catheter sizes. Its extensive distribution network and focus on minimally invasive solutions strengthen its market position.
 

• HAEMONETICS

The company differentiates itself with innovative closure technologies emphasizing safety and efficiency, particularly in high-volume catheterization settings. Its emphasis on procedural standardization and post-procedural patient outcomes provides a competitive edge in clinical adoption.

 

Vascular Closure Device Industry News:

• In June 2025, Vivasure Medical announced the submission of a Premarket Approval (PMA) application to the U.S. FDA for its PerQseal Elite vascular closure system for arterial procedures. The company had also received European CE mark approval for an expanded indication covering large-bore venous closure, building on prior approvals and clinical study results. This development is expected to strengthen the company’s market position by introducing a fully bioresorbable, sutureless solution for both arterial and venous access, enhancing adoption potential globally.
   
• In July 2024, Cordis announced FDA premarket approval for its Mynx Control venous vascular closure device (VCD), designed for access sites ranging from 6 F to 12 F. The device extended the Mynx product technology to midbore venous puncture sites, including electrophysiology procedures. This approval strengthened company’s position in the market by expanding its product portfolio and meeting growing demand for versatile and safe closure solutions.
   
• In August 2024, Haemonetics Corporation announced the release of its VASCADE MVP XL mid-bore venous closure system, making it available to U.S. hospitals. The system featured an innovative collapsible disc technology and a proprietary resorbable collagen patch to promote rapid hemostasis. This launch enhanced Haemonetics’ market presence by expanding its VASCADE portfolio and addressing the growing demand for efficient and safe venous closure solutions.
   
• In May 2022, Teleflex Incorporated announced that it received Health Canada approval for the MANTA vascular closure device. This approval represented a key milestone in the company’s regulatory plan to expand global availability. It strengthened Teleflex’s market presence by providing Canadian clinicians access to its uniquely designed closure device, supporting broader adoption.
   

The vascular closure device market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Device Type

• Active vascular closure devices
  • Collagen plug mediated device
  • Suture-mediated devices
  • Staple/clip-mediated VCD 
• Passive vascular closure devices
  • Haemostasis pads/patches
  • Compression devices

Market, By Access

• Femoral
• Radial

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE